Pyrazole alcohol compound as well as preparation method and application thereof

By developing a pyrazole compound, the problem of single edaravone pathway was solved, and the neuroprotection of multi-pathways was achieved, which was significantly better than the free radical scavenging effect of edaravone, and was used to prevent or treat stroke. Cardiovascular and cerebrovascular diseases and neurodegenerative diseases.

CN118955469AInactive Publication Date: 2024-11-15ANHUI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202410916470.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-09
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

In the prior art, edarafin has a single pathway in neuroprotection and cannot play a role in multiple pathways, making it difficult to effectively prevent or treat stroke, cardiovascular and cerebrovascular diseases and neurodegenerative diseases caused by excessive radicals.

Method used

Develop a pyrazole compound that provides multiple mechanisms to scavenge free radicals, including improving neuronal cell damage caused by peroxides, better than edaravone's scavenging effect, and is used to prepare for the prevention or treatment of stroke , cardiovascular and cerebrovascular diseases and neurodegenerative diseases.

Benefits of technology

This pyrazole alcohol compound is significantly better than edaravone in free radical scavenging effect, and can exert neuroprotective effects through multiple pathways, significantly improving the therapeutic effect of stroke, cardiovascular and cerebrovascular diseases and neurodegenerative diseases caused by free radical overdose. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955469A_ABST
    Figure CN118955469A_ABST
Patent Text Reader

Abstract

The invention provides a pyrazole alcohol compound as well as a preparation method and application thereof, and belongs to the technical field of compounds as well as preparation methods and application thereof. Wherein the pyrazole alcohol compound comprises a compound as shown in a formula (I) or pharmaceutically acceptable salt or prodrug thereof: # imgabs0 # Z is selected from halogen, alkyl, hydroxyl, alkyl hydroxyl or alkyl halide substituted aromatic nucleus, Y is selected from CH3, CF3 or-COCH3, and W is hydroxyl or carbonyl. The pyrazole alcohol compound provided by the invention is applied to drugs for scavenging free radicals, preparing drugs for protecting neuronal cells, preparing drugs for preventing or treating or assisting in treating cerebral apoplexy, cerebral ischemia and ischemia reperfusion, and preparing drugs for preventing or treating or assisting in treating neurodegenerative diseases and complications thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a compound and a preparation method and application thereof, in particular to a pyrazole alcohol compound and a preparation method and application thereof. Background Art

[0002] Normal cell aerobic metabolism produces oxygen- and nitrogen-containing free radicals, including superoxide anion free radicals, nitric oxide free radicals, etc. Free radicals are the products of normal cell physiological activity metabolism. When cells use oxygen, the redox process produces free radicals, usually reactive oxygen species (ROS). Energy failure and oxidative stress caused by excessive ROS can induce cell damage and lead to the occurrence of a variety of diseases, including cancer and stroke, as well as tissue damage in various chronic and degenerative diseases. The brain is one of the organs in the body with high oxygen consumption and high metabolism. Therefore, in brain tissue, such as neurons, free radicals are more likely to be produced, leading to brain tissue damage.

[0003] Ischemic stroke can cause a series of complex ischemic cascade reactions, including excitatory neurotoxicity, oxidative stress, blood-brain barrier damage, inflammatory response, and neuronal apoptosis. The inflammatory response includes the activation of various immune cells such as microglia, macrophages, and T lymphocytes. Microglia release proinflammatory cytokines under the stimulation of excitatory neurotransmitters, and the production of inflammatory-related cytokines and chemokines together induce immune cells such as neutrophils, macrophages, and lymphocytes to adhere to the vascular wall, and then infiltrate the central nervous system, leading to blood-brain barrier damage and cell edema. At the same time, the accumulation of neutrophils in the core area of ​​ischemia further aggravates oxidative stress and blood-brain barrier damage, leading to programmed or non-programmed death of nerve cells. Especially after reperfusion, it will lead to the production of highly harmful ROS, produce oxidative stress, and thus lead to brain tissue damage, with extremely high disability and mortality rates, making patients lose their ability to live independently, and seriously affecting their quality of life.

[0004] Free radical scavengers play a vital role in the human body's defense against free radicals. When pyrazolone compounds exist in the form of isoanions, they can donate an electron in the structure to free radicals, thereby achieving the purpose of free radical scavenging. Edaravone belongs to a class of brain protective agents and is mainly used clinically to treat ischemic stroke. It mainly shows a strong antioxidant effect by eliminating hydroxyl free radicals and inhibiting lipid peroxidation, preventing cell membrane oxidative damage, and inhibiting brain edema and cerebral infarction after cerebral ischemia. In addition to its anti-stroke effect, Edaravone has also been shown to prevent oxidative damage to various extracerebral organs. However, the neuroprotective effect of Edaravone is mainly achieved by scavenging free radicals, so it is necessary to develop a small molecule drug that exerts neuroprotective effects in multiple pathways. Summary of the invention

[0005] In view of the problem that the neuroprotective effect of edaravone in the prior art is produced by a relatively single pathway, the purpose of the present invention is to provide a pyrazolol compound and a preparation method and application thereof, which can be a drug that can exert neuroprotective effects in multiple pathways.

[0006] In the first aspect of the present invention, a pyrazolol compound is provided, wherein the compound comprises a compound as shown in formula (I) or a pharmaceutically acceptable salt, isomer or prodrug thereof:

[0007]

[0008] Wherein, Z is selected from an aromatic ring substituted by halogen, alkyl, hydroxyl, alkylhydroxyl or alkyl halide; Y is selected from CH3, CF3 or -COCH3; and W is hydroxyl or carbonyl.

[0009] Preferably, Z is a six-membered aromatic ring substituted by halogen, alkyl, hydroxy, alkylhydroxy or alkyl halide;

[0010] Preferably, Z is pyridine or pyrimidine substituted by halogen, alkyl, hydroxyl, alkylhydroxyl or alkyl halide;

[0011] Preferred Z is:

[0012] Preferably, the pyrazolol compound is selected from any one of the following compounds or pharmaceutically acceptable salts thereof:

[0013]

[0014] The second aspect of the present invention provides a method for preparing a pyrazole alcohol compound, comprising the following steps:

[0015] (1) Dissolve 1-4 mmol (1 eq) of hydrazine compound raw material in 3-5 mL of glacial acetic acid, add 1.2-1.5 eq of ethyl acetoacetate / ethyl trifluoroacetoacetate and 1 eq of sodium acetate in sequence under stirring, and reflux at 125° C. to obtain compound 2;

[0016] The synthetic route of the pyrazole alcohol compound proposed by the present invention is as follows:

[0017]

[0018] Wherein, the hydrazine compounds include: 5-fluoro-2-hydrazinopyridine, 5-chloro-2-hydrazinopyridine, 5-trifluoromethyl-2-hydrazinopyridine, 5-fluoro-2-hydrazinopyrimidine, 3,5-dichloro-2-hydrazinopyridine, (6-hydrazinopyridine-3-yl)methanol, 3-methyl-2-hydrazinopyridine, 3-chloro-2-hydrazinopyridine, 3-trifluoromethyl-2-hydrazinopyridine, 3,5,6-trimethyl-2-hydrazinopyrazine, (2-hydrazinopyridine-6-yl)methanol;

[0019] Wherein, Z is selected from an aromatic ring substituted by halogen, alkyl, hydroxyl, alkylhydroxyl or alkyl halide; Y is selected from any one of CH3, CF3 or -COCH3; W is hydroxyl or carbonyl;

[0020] Preferably, Z is a six-membered aromatic ring substituted by halogen, alkyl, hydroxy, alkylhydroxy or alkyl halide;

[0021] Preferably, Z is pyridine or pyrimidine substituted by halogen, alkyl, hydroxyl, alkylhydroxyl or alkyl halide;

[0022] Preferred Z is:

[0023] The third aspect of the present invention provides a pharmaceutical composition, which is a pharmaceutical composition comprising the pyrazolol compound, wherein one or more pharmaceutically acceptable salts, isomers, prodrugs, polymorphs or solvent compounds are added to the pyrazolol compound.

[0024] Furthermore, the pharmaceutical composition is in the form of capsules, pills, tablets, granules or injections.

[0025] The fourth aspect of the present invention provides the use of the aforementioned pyrazolol compounds in the preparation of drugs for scavenging free radicals.

[0026] The fifth aspect of the present invention provides the use of the aforementioned pyrazolol compounds in the preparation of drugs for protecting neuronal cells.

[0027] The sixth aspect of the present invention provides the use of the aforementioned pyrazolol compounds in the preparation of drugs for preventing, treating or assisting in the treatment of stroke, cerebral ischemia and ischemia-reperfusion.

[0028] The seventh aspect of the present invention provides the use of the aforementioned pyrazolol compounds in the preparation of drugs for preventing, treating or assisting in the treatment of neurodegenerative diseases and their complications.

[0029] The beneficial effects of the technical solution of the present invention are:

[0030] Compared with the existing technology, the present invention has the following significant characteristics: the pyrazole alcohol compound proposed in the present invention can effectively remove free radicals and improve neuronal cell damage caused by peroxides, especially compared with the set edaravone (free radical scavenger) comparative example, the present invention has excellent free radical removal effect. Therefore, this type of compound plays an important role in the preparation of prevention or treatment of stroke, cardiovascular and cerebrovascular diseases, and neurodegenerative diseases caused by excessive free radicals.

[0031] Other features and advantages of the present invention will be described in the following description, and partly become obvious from the description, or be understood by implementing the present invention. The purpose and other advantages of the present invention can be realized and obtained by the structures pointed out in the description and the drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 This is a characterization diagram of the ORAC antioxidant capacity of the compounds of the present application;

[0033] Figure 2 This is a characterization diagram of the chelating ability of the compounds 2-11 of the present application with different metals;

[0034] Figure 3 This is a characterization diagram of the protective effect of the compound of the present application on cerebral ischemia-reperfusion injury. DETAILED DESCRIPTION

[0035] In order to make the purpose, technical scheme and advantages of the present invention clearer, the implementation scheme of the present application will be described in detail below in conjunction with specific examples. The technical terms and scientific terms used in the present invention have the meanings generally understood by ordinary technicians in the technical field to which the present invention belongs, without other definitions. Without departing from the concept of the present invention, those skilled in the art may make various improvements and changes to the specific implementation methods of the present invention specification, which all belong to the protection scope of the present invention.

[0036] The solvents used in the present invention are all commercially available chemically pure or analytically pure. The structure of the compound is determined by nuclear magnetic resonance (NMR). The NMR measurement is performed using a Bruker AVANCE-600MHz nuclear magnetic resonance spectrometer, the solvent for the measurement is CDCl3 or DMSO-d6, and the internal standard is TMS.

[0037] The preparation method of the above pyrazole amide compounds is exemplified below in conjunction with specific examples.

[0038] Example 1: Preparation of compound 5-fluoro-2-hydrazinopyridine (1-1)

[0039]

[0040] 2,5-Difluoropyridine (905 μL, 10 mmol) was dissolved in ethanol (10 mL), and hydrazine hydrate (85%) (1.55 mL, 50 mmol) was added under stirring, and the reaction was carried out at 125°C for 7 h. After the reaction was completed, the ethanol solvent was removed by concentration under reduced pressure, 30 mL of water was added, and the mixture was extracted with ethyl acetate, and the organic phase was concentrated. The yellow solid 1-1 was obtained by silica gel column chromatography, and the yield was 62%. 1H NMR (600MHz, CDCl3) δ7.99 (s, 1H), 7.30-7.26 (m, 1H), 6.72 (dt, J = 9.1, 2.4Hz, 1H), 5.87 (s, 1H), 3.75-3.37 (m, 2H).

[0041] Example 2: Preparation of compound 5-fluoro-2-hydrazinopyrimidine (1-2)

[0042]

[0043] Intermediate 1-2 is obtained by replacing the raw material of 5-fluoro-2-hydrazinopyridine (1-1) with 2-chloro-5-fluoropyrimidine and reacting with hydrazine hydrate (85%) at high temperature. The reaction process is similar to 1-1, and the product is a white powder 1-2 with a yield of 67%. 1H NMR (600MHz, DMSO-d6) δ8.39 (d, J=1.0Hz, 2H), 8.20 (s, 1H), 4.13 (s, 2H).

[0044] Example 3: Preparation of compound 3,5-dichloro-2-hydrazinopyridine (1-3)

[0045]

[0046] Intermediate 1-3 is obtained by replacing the raw material of 5-fluoro-2-hydrazinopyridine (1-1) with 2-bromo-5-chloropyridine and reacting with hydrazine hydrate (85%) at high temperature. The reaction process is similar to that of 1-1, and the product is a white solid 1-3 with a yield of 69%. 1H NMR (600MHz, CDCl3) δ8.04 (d, J=2.5Hz, 1H), 7.43 (dd, J=8.9, 2.5Hz, 1H), 6.71 (d, J=8.9Hz, 1H), 3.48 (s, 2H).

[0047] Example 4: Preparation of compound (6-hydrazinopyridin-3-yl)methanol (1-4)

[0048]

[0049] Intermediate 1-4 is obtained by replacing the raw material of 5-fluoro-2-hydrazinopyridine (1-1) with 2-chloro-5-hydroxypyridine and reacting with hydrazine hydrate (85%) at high temperature. The reaction process is similar to 1-1, and the product is a green-brown solid 1-4 with a yield of 85%.

[0050] Example 5: Preparation of compound 5-trifluoromethyl-2-hydrazinopyridine (1-5)

[0051]

[0052] Intermediate 1-5 is obtained by replacing the raw material of 5-fluoro-2-hydrazinopyridine (1-1) with 2-chloro-5-trifluoromethylpyridine and reacting with hydrazine hydrate (85%) at high temperature. The reaction process is similar to 1-1, and the product is a white solid 1-5 with a yield of 53%. 1 H NMR (600MHz, DMSO-d6) δ8.28(s,1H),8.26(d,J=2.5Hz,1H),7.69(dd,J=9.0,2.5Hz,1H),6.79(d,J=8.7Hz,1H),4.34(s,2H).

[0053] Example 6: Preparation of compound 1-(5-fluoropyridin-2-yl)-3-trifluoromethyl-1H-pyrazol-5-ol (2-1)

[0054]

[0055] Intermediate 1-1 (635 mg, 5 mmol) was dissolved in glacial acetic acid (5 mL), and ethyl trifluoroacetoacetate (1.10 mL, 7.49 mmol) and sodium acetate (410 mg, 5 mmol) were added under stirring, and refluxed at 125°C for 7 h. After the reaction was completed, no solid was precipitated, and it was extracted with ethyl acetate, and the organic phase was concentrated. The yellow solid 2-1 was obtained by silica gel column chromatography, and the yield was 57%. Melting point: 95.5°C-97.9°C; 1 H NMR (600MHz, CDCl3) δ11.99(s,1H),8.21(d,J=2.9Hz,1H),8.04(dd,J=9.2,4.0Hz,1H),7.71(ddd,J=9.2,7.5,2.9Hz,1H),5.87(s,1H). 13 C NMR (151MHz, CDCl3) δ157.42 (d, J = 254.0Hz), 156.09, 150.19 (d, J = 2.7Hz), 143.75 (q, J = 38.6Hz), 133.27 (d, J = 27 .9Hz), 128.04 (d, J = 20.3Hz), 120.77 (q, J = 268.8Hz), 114.56 (d, J = 5.0Hz), 86.72 (q, J = 2.2Hz); HRMS (m / z): calcd for C9H4F4N3O[MH] - ,246.0296;found,246.0291.

[0056] Example 7: Preparation of compound 1-(5-fluoropyridin-2-yl)-3-methyl-1H-pyrazol-5-ol (2-2)

[0057]

[0058] Intermediate 1-1 (317.5 mg, 2.5 mmol) was dissolved in glacial acetic acid (5 mL), and ethyl acetoacetate (410.25 μL, 3.25 mmol) and sodium acetate (204.89 mg, 2.5 mmol) were added under stirring, and refluxed at 125°C for 7 h. After the reaction was completed, no solid was precipitated by adding water, and the organic phase was extracted with ethyl acetate and concentrated to obtain a white powder 2-2 by silica gel column chromatography, with a yield of 51%. Melting point: 145.4°C-147.2°C; 1 H NMR (600MHz, DMSO-d6) δ12.03(s,1H),8.48-8.46(m,1H),8.43(d,J=3.0Hz,1H),7.88(t,J=8.9Hz,1H),5.11(s,1H),2.17(s,3H). 13 C NMR(151MHz,DMSO-d6)δ163.33,156.44(d,J=248.5Hz),150.48,145.41,135.1 9(d,J=25.7Hz),126.65(d,J=19.9Hz),112.78,93.01,12.47.HRMS(m / z):calcd for C9H9FN3O[M+H] + ,194.0724;found,194.0731.

[0059] Example 8: Preparation of compound 1-(5-chloropyridin-2-yl)-3-methyl-1H-pyrazol-5-ol (2-3)

[0060]

[0061] Intermediate 1-3 (500 mg, 3.48 mmol) was dissolved in glacial acetic acid (4 mL), and ethyl acetoacetate (572.03 μL, 4.53 mmol) and sodium acetate (285.68 mg, 3.48 mmol) were added under stirring, and refluxed at 125°C for 7 h. After the reaction was completed, no solid was precipitated after adding water, and it was extracted with ethyl acetate, and the organic phase was concentrated. After silica gel column chromatography, an orange-yellow solid 2-3 was obtained with a yield of 25%. Melting point: 156.7°C-159.4°C; 1 H NMR (600MHz, DMSO-d6) δ12.00(br s,1H),8.46(d,J=2.5Hz,1H),8.41-8.24(m,1H),8.02(dd,J=8.9,2.6Hz,1H),5.17(s,1H),2.17(s,3H). 13C NMR(151MHz, DMSO-d6)δ162.31,150.94,148.11,146.15,139.11,126.29,113.13,92.23,12.92; HRMS(m / z):calcd for C9H9ClN3O[M+H] + ,210.0429;found,210.0436.

[0062] Example 9: Preparation of compound 3-trifluoromethyl-1-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-5-ol (2-4)

[0063]

[0064] Intermediate 1-5 (450 mg, 2.54 mmol) was dissolved in glacial acetic acid (5 mL), and ethyl trifluoroacetoacetate (580.93 μL, 3.25 mmol) and sodium acetate (208.35 mg, 2.54 mmol) were added under stirring, and refluxed at 125°C for 7 h. After the reaction was completed, no solid was precipitated after adding water, and it was extracted with ethyl acetate, and the organic phase was concentrated. White powder 2-4 was obtained by silica gel column chromatography, with a yield of 45%. Melting point: 67.5°C-69.8°C; 1 H NMR (600MHz, DMSO-d6) δ12.77(s,1H),8.98(d,J=2.4Hz,1H),8.45(dd,J=8.7,2.4Hz,1H),8.00(d,J=8.6Hz,1H),6.06(s,1H). 13 C NMR(151MHz,DMSO-d6)δ155.95,153.68,146.00(q,J=4.1Hz),142.78(q,J=37.7Hz),137.51(q,J=3.3Hz) ,124.19(q,J=33.0Hz),123.88(q,J=272.1Hz),121.45(q,J=269.1Hz),116.71,86.74; HRMS(m / z):calcd for C 10 H4F6N3O[MH] - ,296.0264;found,296.0260.

[0065] Example 10: Preparation of compound 3-methyl-1-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-5-ol (2-5)

[0066]

[0067] Intermediate 1-5 (450 mg, 2.54 mmol) was dissolved in glacial acetic acid (5 mL), and ethyl acetoacetate (417.30 μL, 3.30 mmol) and sodium acetate (20835 mg, 2.54 mmol) were added under stirring, and refluxed at 125°C for 7 h. After the reaction was completed, no solid was precipitated after adding water, and it was extracted with ethyl acetate, and the organic phase was concentrated. White solid 2-5 was obtained by silica gel column chromatography, with a yield of 32%. Melting point: 165.4°C-167.7°C; 1 H NMR (600MHz, CDCl3) δ11.97(s,1H),8.53(s,1H),8.05(dd,J=8.8,2.3Hz,1H),7.98(d,J=8.8Hz,1H),5.46(s,1H),2.26(s,3H). 13 C NMR (151MHz, CDCl3) δ156.91, 156.25, 153.13, 143.20 (q, J = 4.7Hz), 136.89 (q, J = 4.5Hz) ,123.19(q,J=271.8Hz),122.48(q,J=33.9Hz),112.00,89.12,14.68; HRMS(m / z):calcd for C 10 H9F3N3O[M+H] + ,244.0692;found,244.0699.

[0068] Example 11: Preparation of compound 1-(5-fluoropyrimidin-2-yl)-3-trifluoromethyl-1H-pyrazol-5-ol (2-6)

[0069]

[0070] Intermediate 1-2 (320 mg, 2.50 mmol) was dissolved in glacial acetic acid (4 mL), and ethyl trifluoroacetoacetate (441.60 μL, 3.00 mmol) and sodium acetate (204.91 mg, 2.5 mmol) were added under stirring, and refluxed at 125°C for 7 h. After the reaction was completed, solids were precipitated by adding water, and the filter cake was subjected to silica gel column chromatography to obtain a light yellow solid 2-6 with a yield of 37%. Melting point: 156.3°C-158.8°C; 1 H NMR (600MHz, CDCl3) δ11.16(s,1H),8.72(s,2H),5.94(s,1H). 13C NMR (151MHz, CDCl3) δ156.26, 155.44 (d, J = 263.5Hz), 152.98, 146.58 (d, J = 23.3 Hz,×2),145.60(q,J=39.0Hz),120.46(q,J=270.0Hz),87.10; HRMS(m / z):calcd for C8H3F4N4O[MH] - ,247.0248;found,247.0244.

[0071] Example 12: Preparation of compound 1-(3,5-dichloropyridin-2-yl)-3-trifluoromethyl-1H-pyrazol-5-ol (2-7)

[0072]

[0073] 3,5-Dichloro-2-hydrazinepyridine (356.00 mg, 2.00 mmol) was dissolved in glacial acetic acid (4 mL), and ethyl trifluoroacetoacetate (382.92 μL, 2.60 mmol) and sodium acetate (164.05 mg, 2.00 mmol) were added under stirring, and refluxed at 125°C for 6 h. After the reaction was completed, no solid was precipitated after adding water, and it was extracted with ethyl acetate, and the organic phase was concentrated. White solid 2-7 was obtained by silica gel column chromatography, with a yield of 25%. Melting point: 204.3°C-206.4°C; 1 H NMR (600MHz, DMSO-d6) δ12.52(s,1H),8.71(d,J=2.3Hz,1H),8.60(d,J=2.3Hz,1H),5.93(s,1H). 13 C NMR (151MHz, DMSO-d6) δ155.33, 147.02, 145.28, 142.21 (q, J=37.4Hz), 139.75, 133.38, 129.71, 121.56 (q, J=268.6Hz), 84.80; HRMS (m / z): calcd for C9H5Cl2F3N3O[M+H] + ,297.9756;found,297.9768.

[0074] Example 13: Preparation of compound 2-(3,5-dichloropyridin-2-yl)-5-methyl-2,4-dihydro-3H-pyrazol-3-one (2-8)

[0075]

[0076] 3,5-Dichloro-2-hydrazinepyridine (317.5 mg, 3.00 mmol) was dissolved in glacial acetic acid (4 mL), and ethyl acetoacetate (492.73 μL, 3.90 mmol) and sodium acetate (246.08 mg, 3.00 mmol) were added under stirring, and refluxed at 125°C for 7 h. After the reaction was completed, no solid was precipitated after adding water, and it was extracted with ethyl acetate, and the organic phase was concentrated. The white powder 2-8 was obtained by silica gel column chromatography, and the yield was 17.50%. Melting point: 157.2°C-159.4°C; 1 H NMR (600MHz, CDCl3) δ8.44(d,J=2.2Hz,1H),7.88(d,J=2.2Hz,1H),3.44(s,2H),2.22(s,3H). 13 C NMR(151MHz, CDCl3)δ170.62,157.75,146.22,145.24,138.81,131.67,128.38,41.56,17.23; HRMS(m / z):calcd for C9H8Cl2N3O[M+H] + ,244.0039;found,244.0047.

[0077] Example 14: Preparation of Compound 1-(5-(Hydroxymethyl)pyridin-2-yl)-3-(trifluoromethyl)-1H-pyrazol-5-ol (2-9)

[0078]

[0079] Intermediate 1-4 (250.00 mg, 1.80 mmol) was dissolved in glacial acetic acid (5 mL), and ethyl trifluoroacetoacetate (344.00 μL, 2.34 mmol) and sodium acetate (147.38 mg, 1.80 mmol) were added under stirring, and refluxed at 125°C for 5 h. After the reaction was completed, no solid was precipitated by adding water, and it was extracted with ethyl acetate, and the organic phase was concentrated. White solid 2-9 was obtained by silica gel column chromatography, with a yield of 25%. Melting point: 80.4°C-82.5°C; 1 H NMR (600MHz, CDCl3) δ12.64(s,1H),8.35(s,1H),8.04-7.87(m,2H),5.86(s,1H),5.15(s,2H). 13 C NMR (151MHz, CDCl3) δ156.80, 153.68, 145.33, 144.00 (q, J = 38.7Hz), 140.67, 129.78, 120.80 (q, J = 269.3Hz), 112.75, 86.58 (q, J = 2.1Hz), 62.79.

[0080] Example 15: Preparation of Compound 1-(5-(Hydroxymethyl)pyridin-2-yl)-3-methyl-1H-pyrazol-5-ol (2-10)

[0081]

[0082] Intermediate 1-4 (347.50 mg, 2.50 mmol) was dissolved in glacial acetic acid (5 mL), and ethyl acetoacetate (410.18 μL, 3.25 mmol) and sodium acetate (204.85 mg, 2.50 mmol) were added under stirring, and refluxed at 125°C for 7 h. After the reaction was completed, no solid was precipitated after adding water, and it was extracted with ethyl acetate, and the organic phase was concentrated. Yellow solid 2-10 was obtained by silica gel column chromatography, with a yield of 20%. Melting point: 101.4°C-103.5°C; 1 H NMR (600MHz, CDCl3) δ7.96-7.94(m,1H),7.94-7.90(m,1H),7.28(d,J=7.2Hz,1H),5.85(s,1H),5.23(s,2H),2.19(d,J=0.9Hz,3H); 13 C NMR (151MHz, CDCl3) δ170.82,157.13,153.96,152.94,141.46,119.60,112.32,86.95,86.94,65.13,21.05.

[0083] Example 16: Preparation of compound 3-methyl-1-(3-methylpyridin-2-yl)-1H-pyrazol-5-ol (2-11)

[0084]

[0085] 3-Methyl-2-hydrazinepyridine (369.48 mg, 3.00 mmol) was dissolved in glacial acetic acid (5 mL), and ethyl acetoacetate (492.76 μL, 3.90 mmol) and sodium acetate (246.09 mg, 3.00 mmol) were added under stirring, and refluxed at 125°C for 7 h. After the reaction was completed, no solid was precipitated after adding water, and it was extracted with ethyl acetate, and the organic phase was concentrated. Reddish solid 2-11 was obtained by silica gel column chromatography, with a yield of 32%. Melting point: 129.7°C-132.5°C; 1 H NMR (600MHz, DMSO-d6) δ8.41(d,J=4.6Hz,1H),7.86(d,J=7.6Hz,1H),7.42(dd,J=7.6,4.7Hz,1H),5.28(s,1H),2.26(s,3H),2.16(s,3H). 13C NMR(151MHz,DMSO-d6)δ149.14,148.24,146.23,145.72,139.83,129.55,123.22,86.01,16.92,13.40; HRMS(m / z):calcd for C9H 10 N3O[M+H] + ,176.0818;found,176.0822.

[0086] Example 17: Preparation of Compound 1-(3-chloropyridin-2-yl)-3-trifluoromethyl-1H-pyrazol-5-ol (2-12)

[0087]

[0088] 3-Chloro-2-hydrazinepyridine (200.00 mg, 1.39 mmol) was dissolved in glacial acetic acid (3.5 mL), and ethyl trifluoroacetoacetate (266.73 μL, 1.81 mmol) and sodium acetate (114.27 mg, 1.39 mmol) were added under stirring, and refluxed at 125°C for 5 h. After the reaction was completed, no solid was precipitated after adding water, and the mixture was extracted with ethyl acetate, and the organic phase was concentrated. After silica gel column chromatography, a light yellow solid 2-12 was obtained with a yield of 27.24%. Melting point: 121.4°C-124.5°C; 1 H NMR (600MHz, CDCl3) δ8.33(dd,J=4.8,1.6Hz,1H),8.03(dd,J=8.1,1.6Hz,1H),7.31(dd,J=8.1,4.8Hz,1H),5.89(s,1H). 13 C NMR (151MHz, CDCl3) δ156.69,148.70,143.83,143.41,142.98(q,J=38.6Hz),122.70,122.60,120.79(q,J=269.4Hz),86.25(q,J=2.3Hz); HRMS(m / z):calcd for C9H6ClF3N3O[M+H] + ,264.0146;found,264.0156.

[0089] Example 18: Preparation of Compound 1-(3-chloropyridin-2-yl)-3-methyl-1H-pyrazol-5-ol (2-13)

[0090]

[0091] 3-Chloro-2-hydrazinepyridine (430.00 mg, 2.99 mmol) was dissolved in glacial acetic acid (5 mL), and ethyl acetoacetate (491.95 μL, 3.89 mmol) and sodium acetate (245.69 mg, 2.99 mmol) were added under stirring, and refluxed at 125°C for 7 h. After the reaction was completed, no solid was precipitated after adding water, and it was extracted with ethyl acetate, and the organic phase was concentrated. Yellow solid 2-13 was obtained by silica gel column chromatography, and the yield was 16.70%. Melting point: 148.1°C-150.4°C; 1 H NMR (600MHz, CDCl3) δ8.55(dd,J=4.7,1.6Hz,1H),7.95(dd,J=8.1,1.6Hz,1H),7.43(dd,J=8.1,4.7Hz,1H),5.85(s,1H),2.56(s,3H). 13 CNMR (151MHz, CDCl3) δ159.62,153.24,147.59,145.73,139.82,128.41,125.71,105.72,19.78.

[0092] Example 19: Preparation of Compound 3-trifluoromethyl-1-(3-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-5-ol (2-14)

[0093]

[0094] 3-Trifluoromethyl-2-hydrazinepyridine (425.00 mg, 2.40 mmol) was dissolved in glacial acetic acid (5 mL), and ethyl trifluoroacetoacetate (424.09 μL, 2.88 mmol) and sodium acetate (196.83 mg, 2.40 mmol) were added under stirring, and refluxed at 125°C for 7 h. After the reaction was completed, no solid was precipitated after adding water, and the mixture was extracted with ethyl acetate, and the organic phase was concentrated. After silica gel column chromatography, a light yellow powder 2-14 was obtained with a yield of 28%. Melting point: 124.4°C-127.5°C; 1 H NMR (600MHz, CDCl3) δ11.79(s,1H),8.56(d,J=5.0Hz,1H),8.36(d,J=8.0Hz,1H),7.47(dd,J=8.3,5.0Hz,1H),5.89(s,1H). 13CNMR (151MHz, CDCl3) δ156.82, 150.34, 148.53, 144.09 (q, J = 39.1Hz), 140.25 (q, J = 6.0Hz), 121.9 0(q,J=272.9Hz),121.39,120.63(q,J=269.4Hz),117.70(q,J=35.5Hz),86.61; HRMS(m / z):calcd for C 10 H6F6N3O[M+H] + ,298.0410;found,298.0422.

[0095] Example 20: Preparation of compound 3-methyl-1-(3-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-5-ol (2-15)

[0096]

[0097] 3-Trifluoromethyl-2-hydrazinepyridine (340.00 mg, 1.92 mmol) was dissolved in glacial acetic acid (4 mL), and ethyl acetoacetate (315.29 μL, 2.50 mmol) and sodium acetate (157.46 mg, 1.92 mmol) were added under stirring, and refluxed at 125°C for 5 h. After the reaction was completed, solids were precipitated by adding water, and the filter cake was filtered by silica gel column chromatography to obtain white solid 2-15 with a yield of 23%. Melting point: 162.9°C-165.6°C; 1 H NMR (600MHz, CDCl3) δ8.81(dd,J=4.9,1.7Hz,1H),8.23(dd,J=8.0,1.7Hz,1H),7.62(dd,J=8.0,4.8Hz,1H),5.86(s,1H),2.54(s,3H). 13 C NMR (151MHz, CDCl3) δ159.53, 153.15, 152.45, 145.46, 137.35 (q, J = 4.6Hz), 124.78, 123.69 (q, J = 33.7Hz), 122.08 (q, J = 273.6Hz), 105.95, 19.77.

[0098] Example 21: Preparation of Compound 3-methyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol (2-16)

[0099]

[0100] 2-Hydrazine pyridine (327.39 mg, 3.00 mmol) was dissolved in glacial acetic acid (5 mL), and ethyl acetoacetate (492.77 μL, 3.90 mmol) and sodium acetate (246.09 mg, 3.00 mmol) were added under stirring, and refluxed at 125°C for 7 h. After the reaction was completed, solids were precipitated by adding water, and the filter cake was filtered and subjected to silica gel column chromatography to obtain a light yellow solid 2-16 with a yield of 45%. Melting point: 101.2°C-103.4°C; 1 H NMR (600MHz, CDCl3) δ12.73(s,1H),8.23(dt,J=5.1,1.3Hz,1H),7.84(d,J=1.8Hz ,2H),7.83(dd,J=8.6,1.7Hz,1H),7.11(ddd,J=6.7,5.1,2.2Hz,1H),5.42(s,1H). 13 C NMR(151MHz, CDCl3)δ157.59,151.86,148.92,145.48,140.20,119.88,112.16,89.01; HRMS(m / z):calcd for C 10 H 12 N4O[M+H] + ,205.1084;found,205.1091.

[0101] Example 22: Preparation of Compound 1-(pyrimidin-2-yl)-3-(trifluoromethyl)-1H-pyrazol-5-ol (2-17)

[0102]

[0103] 2-Hydrazine (385.42 mg, 3.50 mmol) was dissolved in glacial acetic acid (5 mL), and ethyl trifluoroacetoacetate (813.32 μL, 4.55 mmol) and sodium acetate (287.11 mg, 3.50 mmol) were added under stirring, and refluxed at 125°C for 7 h. After the reaction was completed, solids were precipitated by adding water, and the filter cake was discarded. The filtrate was extracted with ethyl acetate, and the organic phase was concentrated. White powder 2-17 was obtained by silica gel column chromatography with a yield of 22%. Melting point: 86.7°C-88.0°C; 1 H NMR (600MHz, DMSO-d6) δ12.38(s,1H),8.97(d,J=4.9Hz,2H),7.63(t,J=4.9Hz,1H),6.05(s,1H). 13C NMR (151MHz, DMSO-d6) δ159.69 (×3), 156.13, 142.43 (q, J = 37.5Hz), 121.54 (q, J = 269.1Hz), 120.65, 86.35 (q, J = 2.2Hz); HRMS (m / z): calcd for C8H5F3N4O[M+H] + ,231.0488;found,231.0494.

[0104] Example 23: Preparation of Compound 1-(4,6-dimethylpyrimidin-2-yl)-3-methyl-1H-pyrazol-5-ol (2-18)

[0105]

[0106] 2-Hydrazino-4,6-dimethylpyrimidine (276.00 mg, 2.00 mmol) was dissolved in glacial acetic acid (3 mL), and ethyl acetoacetate (260.28 μL, 2.60 mmol) and sodium acetate (163.85 mg, 2.00 mmol) were added under stirring, and refluxed at 125°C for 5 h. After the reaction was completed, no solid was precipitated after adding water, and the mixture was extracted with ethyl acetate, and the organic phase was concentrated. White powder 2-18 was obtained by silica gel column chromatography, with a yield of 41.76%. Melting point: 96.2°C-98.5°C; 1 H NMR (600MHz, CDCl3) δ12.43(br s,1H),6.88(s,1H),5.46(s,1H),2.56(s,6H),2.30(s,3H). 13 C NMR(151MHz, CDCl3)δ168.55,157.06(×2),156.96,153.08,116.45,88.69,24.00(×2),14.91; HRMS(m / z):calcd for C 10 H 12 N4O[M+H] + ,205.1084;found,205.1091.

[0107] Example 24: Preparation of Compound 3-(Trifluoromethyl)-1-(3,5,6-trimethylpyrazin-2-yl)-1H-pyrazol-5-ol (2-19)

[0108]

[0109] 2-Hydrazino-3,5,6-trimethylpyrazine (200.00 mg, 1.31 mmol) was dissolved in glacial acetic acid (4 mL), and ethyl trifluoroacetoacetate (232.26 μL, 1.58 mmol) and sodium acetate (107.80 mg, 1.31 mmol) were added under stirring, and refluxed at 125°C for 4 h. After the reaction was completed, no solid was precipitated after adding water, and the mixture was extracted with ethyl acetate, and the organic phase was concentrated. Yellow powder 2-19 was obtained by silica gel column chromatography, with a yield of 50.32%. Melting point: 108.8°C-111.1°C; 1 H NMR (600MHz, DMSO-d6) δ12.32(s,1H),5.93(s,1H),2.55(s,3H),2.49(s,3H),2.26(s,3H). 13 C NMR(151MHz,DMSO-d6)δ154.95,153.96,149.79,146.99,141.64,141.63(q,J= 37.4Hz), 121.69 (q, J=268.7Hz), 84.86, 21.81, 21.31, 19.40; HRMS (m / z): calcd for C 11 H 12 F3N4O[M+H] + ,273.0958;found,273.0963.

[0110] Example 25: Preparation of Compound 1-(6-(Hydroxymethyl)pyridin-2-yl)-3-methyl-1H-pyrazol-5-ol (2-20)

[0111]

[0112] (2-Hydrazinopyridin-6-yl)methanol (278.32 mg, 2 mmol) was dissolved in glacial acetic acid (3.5 mL), and ethyl acetoacetate (303.23 μL, 2.4 mmol) and sodium acetate (164 mg, 2 mmol) were added under stirring, and refluxed at 125° C. for 6 h. After the reaction was completed, no solid was precipitated after adding water, and the mixture was extracted with ethyl acetate, and the organic phase was concentrated and subjected to silica gel column chromatography to obtain white powder 2-23 with a yield of 25%. 1 HNMR (600MHz, CDCl3) δ7.95(t,J=7.8Hz,1H),7.92(d,J=8.2Hz,1H),7.28(d,J=7.3Hz,1H),5.85(d,J=1.5Hz,1H),5.23(s,2H),2.20(d,J=1.6Hz,3H); 13C NMR (151MHz, CDCl3) δ170.40,156.70,153.54,152.52,141.03,119.18,111.90,86.53,64.71,20.63.

[0113] Example 26: Preparation of Compound 1-(1-(3,5-dichloropyridin-2-yl)-5-hydroxy-1H-pyrazol-3-yl)ethan-1-one (2-21)

[0114]

[0115] 3,5-Dichloro-2-pyridinehydrazine (317.5 mg, 3.00 mmol) was dissolved in glacial acetic acid (3.5 mL), and ethyl 3-acetyl-4-oxopentanoate (677.33 μL, 3.6 mmol) and sodium acetate (246.53 mg, 3 mmol) were added under stirring, and refluxed at 125°C for 6 h. After the reaction was completed, no solid was precipitated after adding water, and the mixture was extracted with ethyl acetate, and the organic phase was concentrated and subjected to silica gel column chromatography to obtain a yellow oil 2-24 with a yield of 50%. 1 H NMR (600MHz, CDCl3) δ8.45-8.44(m,1H),7.92(dd,J=2.3,0.6Hz,1H),3.41(s,2H),2.30(s,3H); 13 C NMR (151MHz, CDCl3) δ149.74,147.27,145.91,139.31,138.81,132.03,129.04,111.12,29.73,14.12.

[0116] Example 27: DPPH free radical scavenging experiment

[0117] Preparation of DPPH test solution: Take DPPH solid and prepare it into 50μM DPPH test solution with an absorbance of 0.45. Preparation of sample solution: The sample is dissolved in a suitable solvent to prepare a 20mM solution. Before the test, the 20mM solution of the compound to be tested is diluted with ethanol to 500μM, and edaravone is used as a positive control compound. It is then diluted with ethanol to 40μM for testing. A value measurement (test group): In a 96-well plate, use a pipette to take 40μL of the ethanol solution of the compound to be tested, and then add 160μL of DPPH solution. All the above tests were performed in parallel three times. At room temperature for 8h, measure the A519 nm value. A0 value measurement (blank group): Use a pipette to take 40μL of ethanol solution, and then add 160μL of DPPH solution. The measured A value is A0. The experimental results (Table 1) show that most of the target compounds showed better DPPH scavenging ability than edaravone, among which compounds 2-3, 2-8, 2-11, and 2-18 had scavenging ability twice as strong as that of edaravone.

[0118] Table 1. Scavenging ability of compounds on DPPH (%)

[0119]

[0120] Example 28: ABTS free radical scavenging experiment

[0121] Preparation of ABTS working stock solution: 7.4mmol / L ABTS solution and 2.6mmol / L potassium persulfate solution were mixed in a volume ratio of 1:1, and the ABTS working stock solution was obtained by standing at room temperature in the dark for 12h; sample solution preparation: the sample was dissolved in DMSO to prepare a 20mM solution. Before the test, the 20mM test compound solution was diluted with ethanol to 20μM, 40μM, and 80μ. Measurement of A0 value (blank group): ABTS working stock solution was diluted with PBS, and 40μL of ethanol solution was taken in a 96-well plate with a pipette, and then 160μL of the diluted ABTS working stock solution was added. The measured A value is A0; A value measurement (test group): In a 96-well plate, 40μL of the ethanol solution of the test compound was taken with a pipette, and then 160μL of the diluted ABTS working stock solution was added; all the above tests were performed in parallel three times. After 15 minutes of reaction at room temperature in the dark, the A value was detected at 734 nm. The experimental results (Table 2) showed that most of the target compounds showed better DPPH scavenging ability than edaravone, among which compounds 2-4, 2-6, 2-8, 2-16, 2-17, and 2-18 had significantly better scavenging ability than edaravone, and 2-16 had the strongest scavenging ability for ABTS, reaching 69.14%.

[0122] Table 2. Ability of compounds to scavenge ABTS (%)

[0123]

[0124] Example 29: ORAC fluorescence test antioxidant capacity

[0125] The antioxidant activity of the compounds was determined by oxygen radical absorbance capacity-fluorescein (ORAC-FL). Trolox (Tro) was used as a positive control compound. The test compound (20 μL, 4 μM) and fluorescein solution (120 μL, 117 nM) were added to a 96-well black board in sequence. The test plate was incubated at 37°C for 15 minutes. Subsequently, azobisisobutyramidine hydrochloride (AAPH, 60 μL, 40 mM) was added to the system with a final volume of 200 μL to start the reaction. Immediately after the addition of AAPH, fluorescence was recorded once per minute in a Tecan 96 microplate reader (lex 485 nm, lem 525 nm, 37°C) for 120 minutes. The reaction mixture was prepared in triplicate. The blank control group was measured without the use of antioxidants or without AAPH and antioxidants. ORAC (TE value) was expressed as Trolox equivalent (mean ± SD) using a standard curve calculated for each assay. The experimental results are shown in Tables 3 and Figure 1 Table 3 shows that the antioxidant capacity of compounds 2-11 and 2-18 is better than that of edaravone, and their ORAC values ​​are 1.88 and 1.56, respectively. Figure 1 The ORAC antioxidant capacity characterization diagram of some compounds. Figure 1 Among them, compounds 2-8, 2-11, and 2-18 showed excellent antioxidant capacity compared with Trolox. Among them, compound 2-11 showed the best antioxidant capacity, and Figure 1 B is the curve of relative fluorescence unit (RFU) changing with time, indicating that compared with the blank and Trolx, compound 2-11 can significantly inhibit the fluorescence decay, showing its excellent antioxidant ability.

[0126] Table 3. Antioxidant ability test data of compounds (TE)

[0127]

[0128]

[0129] Example 30: Metal Chelation Test

[0130] The metal chelating ability of the target compound was investigated by ultraviolet spectroscopy. Redox-active metals (such as iron and copper) undergo redox cycle reactions and produce reactive free radicals, such as superoxide anion radicals and nitric oxide in biological systems. The disruption of metal ion homeostasis may lead to oxidative stress, in which the formation of reactive oxygen species increases, subsequently inducing DNA damage, lipid peroxidation and other effects. This effect is involved in cardiovascular disease, atherosclerosis, neurological diseases, chronic inflammation and other diseases. The mechanism of metal-induced free radical formation is affected by cellular antioxidants. Many low molecular weight antioxidants (vitamin C, vitamin E, glutathione, etc.) can chelate metal ions, thereby reducing the generation of reactive oxygen species. Similarly, compounds that can chelate with metal ions may improve their free radical scavenging ability.

[0131] The metal salts used in the test are AlCl3, CaCO3, MgSO4, K2CO3, CuI, CuCl2, FeSO4, FeCl3 and ZnCl2. A methanol solution of the test compound 2-10 (1.0 mL, 300 μM) was added to a methanol solution containing metal ions (1.0 mL, 300 μM), allowed to stand at room temperature for 2 hours, and then the solution was transferred to a quartz cell to measure the absorbance of the solution at 200-550 nm. For selected experimental results, see Figure 2 , compared with 2-10, 2-10 has a maximum absorption peak at 250nm after adding FeCl3, FeSO4, ZnCl2 and CuI. In addition, with the addition of CuCl2, an additional absorption peak appears in the absorption spectrum at 205nm, and the minimum absorption peak moves to 220nm. It is worth noting that after adding CuCl2, the maximum absorption peak at 205nm moves to 310nm, which indicates that compound 2-10 and Cu 2+ Has a chelating effect.

[0132] Example 31: Evaluation of the protective effect of oxygen glucose deprivation / reoxygenation (OGD / R)-induced damage in human neuroblastoma cells

[0133] Human neuroblastoma cells specifically use SH-SY5Y cells. SH-SY5Y cells are derived from human bone marrow and are a subclone of the neuroblastoma cell line. Their morphology, physiology, and biochemical functions are similar to those of human cells. They can be transformed into neuron-like cells and have the advantages of simple and rapid large-scale amplification, reproducibility, low cost, and no ethical issues compared to the culture of primary neurons. They are widely used in in vitro experimental studies of nervous system diseases, such as stroke, Parkinson's disease, Alzheimer's disease, etc. Relationship between oxidative damage and the nervous system: The biochemical characteristics of the central nervous system make it particularly susceptible to oxidative damage. Various studies have determined that oxidative damage can impair the normal function of the central nervous system, leading to neurodegeneration and neuronal death. Oxidative damage involves multiple mechanisms of nucleic acid, protein and lipid oxidation, leading to progressive brain damage. These mechanisms include mitochondrial dysfunction, excessive production of reactive oxygen and nitrogen species, insufficient antioxidant defenses, inflammatory responses, abnormalities of the blood-brain barrier, etc. All these dysfunctions are not only related to stroke but also to the pathogenesis of neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, Huntington's disease or amyotrophic lateral sclerosis.

[0134] The experimental method is: take a bottle of cells in logarithmic growth phase, add trypsin cell digestion solution to digest, so that the adherent cells fall off, and prepare a concentration of 8×10 4 100 μL of cell suspension (8×10 cells / mL) was added to each well of a 96-well cell culture plate. 3 cells), and the plate was placed in a 37°C, 5% CO2 incubator for 24 hours. After 24 hours, DMEM was replaced with EBSS. The cells were placed in a closed incubator (C-31, Mitsubishi Corporation, Japan) equipped with a biological bag and cultured for 5 hours. After that, DMEM containing different concentrations of compounds was cultured in a 37°C, 5% CO2 incubator for 24 hours. Finally, 15 μL of MTT solution (5 mg / mL) was added to each well and incubated in a 37°C shaker for 4 hours, the supernatant of each well was discarded, and 100 μL of DMSO was added to each well, and shaken on a cell shaker for 10 minutes. Finally, the OD value was read at a wavelength of 492 nm with a multifunctional microplate reader to calculate the cell growth inhibition rate. The experimental results of some compounds are shown in Table 4: In Table 4, it can be seen from the cell survival rate that the survival rate of the damaged group decreased to 72% compared with the blank group, while edaravone can improve the cell survival rate. The representative compound 2-15 has a protective effect on SH-SY5Y cell damage induced by OGD / R that is better than edaravone.

[0135] Table 4. OGD / R induced SH-SY5Y cells

[0136]

[0137] Example 32: Evaluation of the protective effect on cerebral ischemia induced by middle cerebral artery occlusion (MCAO) model in mice

[0138] Preparation of the compound: accurately weigh 10 mg of the compound, add 0.5 mL of PEG, then add 9.5 mL of PBS, and dissolve by ultrasonication to prepare a 1 mg / mL solution;

[0139] Administration and dosage: The administration method is intraperitoneal injection, and the dosage is 10 mg / kg; the rats in the negative control group (MCAO model group) were intraperitoneally injected with an equal volume of normal saline. The middle cerebral artery occlusion (MCAO) model was used to induce cerebral ischemia. After ICR mice were anesthetized with 2% chloral hydrate (0.2 mL / 10 g), the animals were fixed on the operating table in a supine position, the skin was incised along the midline of the neck, the neck muscle tissue was bluntly separated, the right common carotid artery (CCA) was exposed and carefully freed, the accompanying vagus nerve was gently peeled off, the external carotid artery branch (ECA) running inward and superficial was ligated and cut, and the pterygopalatine artery, which was a branch artery running outward near the base of the skull, was separated and ligated. The proximal end of the CCA was ligated with a surgical thread, and a small opening was cut at the distal end of the ligature with ophthalmic scissors. The nylon thread (diameter 0.22 mm) was inserted along the small opening, and the thread was stopped when a slight resistance was felt after about 9±1 mm. The insertion depth of the wire tie was determined according to the mark, and the extravascular part of the wire tie was ligated and fixed to prevent the wire tie from slipping. After 2 hours of right cerebral ischemia, about 10 mm of the fishing line in the lumen of the internal carotid artery was carefully withdrawn to allow blood flow in the internal carotid artery to reperfuse. The skin was sutured and the rats were returned to the cage for careful feeding. The same surgical procedure was performed on sham-operated rats, but the middle cerebral artery was not blocked. The animal body temperature was kept constant at 37±0.5℃ during the operation. The drug was administered immediately after cerebral ischemia and reperfusion, and the infarct volume was measured by TTC staining 72 hours after administration. The experimental results of some compounds are shown in the figure. Figure 3 As shown: Figure 3 A in the middle is the TTC staining image of the coronal sections of the brains of the four groups of mice: SHAM, MCAO, 2-9, and 2-11. The red tissue in the figure is the normal brain tissue, and the white tissue is the infarcted brain tissue; Figure 3 B is a graph showing the infarct volume measurement data, from which it can be seen that compound 2-11 can significantly reduce the infarct volume in ischemia-reperfusion mice, from about 42% to about 25%.

[0140] Finally, it should be noted that the above is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, it is still possible for those skilled in the art to modify the technical solutions described in the aforementioned embodiments or to make equivalent substitutions for some of the technical features therein. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A pyrazole alcohol compound, characterized in that: Contains a compound represented by formula (I) or a pharmaceutically acceptable salt or prodrug thereof: Wherein, Z is selected from an aromatic ring substituted by halogen, alkyl, hydroxyl, alkylhydroxyl or alkyl halide, Y is selected from CH3, CF3 or -COCH3, and W is hydroxyl or carbonyl.

2. The pyrazolol compound according to claim 1, characterized in that Z is a six-membered aromatic ring substituted by halogen, alkyl, hydroxy, alkylhydroxy or alkyl halide; Z is pyridine or pyrimidine substituted by halogen, alkyl, hydroxy, alkylhydroxy or alkyl halide.

3. The pyrazolol compound according to claim 2, characterized in that: Z is:

4. The pyrazolol compound according to claim 1, characterized in that Selected from any one of the following compounds or pharmaceutically acceptable salts thereof:

5. The method for preparing a pyrazole alcohol compound according to any one of claims 1 to 4, characterized in that: The following steps are involved: The hydrazine compound raw material is dissolved in glacial acetic acid, and 1.2-1.5 eq of ethyl acetoacetate / ethyl trifluoroacetoacetate and 1 eq of sodium acetate are added in sequence under stirring and refluxed to obtain compound 2; The synthetic route of the pyrazole alcohol compound is as follows: Wherein, the hydrazine compounds include: 5-fluoro-2-hydrazinepyridine, 5-chloro-2-hydrazinepyridine, 5-trifluoromethyl-2-hydrazinepyridine, 5-fluoro-2-hydrazinepyrimidine, 3,5-dichloro-2-hydrazinepyridine, (6-hydrazinepyridine-3-yl)methanol, 3-methyl-2-hydrazinepyridine, 3-chloro-2-hydrazinepyridine, 3-trifluoromethyl-2-hydrazinepyridine, 3,5,6-trimethyl-2-hydrazinepyrazine, (2-hydrazinepyridine-3-yl)methanol, (2-hydrazinepyridine-6-yl)methanol; Wherein, Z is selected from an aromatic ring substituted by halogen, alkyl, hydroxyl, alkylhydroxyl or alkyl halide; Y is selected from any one of CH3, CF3, -COCH3; W is hydroxyl or carbonyl; Preferably, Z is a six-membered aromatic ring substituted by halogen, alkyl, hydroxy, alkylhydroxy or alkyl halide; Preferably, Z is pyridine or pyrimidine substituted by halogen, alkyl, hydroxyl, alkylhydroxyl or alkyl halide; Preferred Z is:

6. A pharmaceutical composition, characterized in that A pyrazolol compound comprising any one of claims 1 to 4; Preferably, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients; Preferably, the pharmaceutical composition is in the form of capsules, pills, tablets, granules or injections.

7. Use of the pyrazolol compound according to any one of claims 1 to 4 in the preparation of a drug for scavenging free radicals.

8. Use of the pyrazolol compound according to any one of claims 1 to 4 in the preparation of a drug for protecting neuronal cells.

9. Use of the pyrazolol compound according to any one of claims 1 to 4 in the preparation of a medicament for preventing, treating or assisting in the treatment of stroke, cerebral ischemia and ischemia-reperfusion.

10. Use of the pyrazolol compound according to any one of claims 1 to 4 in the preparation of a medicament for preventing, treating or assisting in the treatment of neurodegenerative diseases and their complications.

Citation Information

Patent Citations

  • Pyrazole alcohol compound, pharmaceutical composition thereof and application thereof to drugs

    CN108558833A